Welcome to NLS Pharma

We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity. We are creating new approaches to treat mental and behavioral disorders, and to enhance cognitive function in healthy people.


Our multidisciplinary Team, led by professionals with a long track record in drug development and management, relies on highly skilled personnel with unique competence in developing integrated solutions.

Latest News

  • August 29, 2016
    NLS Pharma announces start of its phase 2 trial for Mazindol in adult ADHD patients
  • July 11, 2016
    Mazindol granted orphan drug designation in the US & Europe for treatment of Narcolepsy
  • June 16, 2016
    FDA accepts IND for Phase II Study of Mazindol in Adults with ADHD
  • May 12, 2016
    NLS Pharma Announces IND submission for Controlled-Release Mazindol to Treat Adults with ADHD.
Contact us

NLS Pharma is very interested in hearing from you. Please find general contact information below.

Breitenweg 10
CH-6370 Stans NW

T: +41 41 618 80 00
F: +41 41 618 80 09

Your Name (required)

Your Email (required)


Your Message